Dr Lisette Nixon
Teams and roles for Lisette Nixon
Research Fellow - Senior Trial Manager in Solid Tumours
Overview
I joined the Wales Cancer Trials Unit as a Trial Manager in September 2006 initially as manager for the SCOPE 1 trial. I then took on co-ordination of the WCTU Translational Working Group and became a member of the NCRI Radiotherapy Trials Quality Assurance group. I also became Trial Manager of I-START. I was promoted to Senior Trial Manager role in July 2010, taking on line management of the Trial Managers within the WCTU and also became the Trial Manager for ROCS. I now have an active role in oversight of many of the trials on the WCTU portfolio, in particular lung and gastrointestinal areas. I have provided short term trial management of SCALOP, NEOSCOPE and SCOPE2, currently only managing I-START.
I have developed a particular specialism is Chemo-radiotherapy and Radiotherapy trials, and now have a role in developing these trials. I have recently submitted funding bids in for additional trials in this area.
Previous research experience includes clinical laboratory research in the respiratory medicine department of Cardiff University, in particular in both Cystic Fibrosis and COPD. I also spent a number of years testing of new chemical entities as an assistant pharmacologist in the pharmaceutical industry.
I have a BSc in Pharmacology, a PhD in respiratory medicine/cell biology, and a PGCE (PCET) with experience of teaching in higher education.
Publication
2026
- Wallis, L. et al., 2026. The QuinteT recruitment intervention and its role in oncology randomised controlled trials [Editorial]. Clinical Oncology 49 103976. (10.1016/j.clon.2025.103976)
2025
- Ibrahim, H. et al., 2025. ColoCap: determining the diagnostic accuracy of colon capsule endoscopy compared with standard colonoscopy in patients at risk of colorectal disease – a study protocol. BMJ Open 15 (9) e104661. (10.1136/bmjopen-2025-104661)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
2024
- Ajakaiye, A. et al., 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting Dublin, Ireland 16-18 October 2024. Vol. 34.BMJ Publishing Group. , pp.A350-A351. (10.1136/ijgc-2024-IGCS.611)
- Holland-Hart, D. et al. 2024. The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. BMJ Open 14 (9) e076394. (10.1136/bmjopen-2023-076394)
- O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
2023
- Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress Istanbul, Turkey 28 September - 01 October 2023. BMJ Publishing Group(10.1136/ijgc-2023-ESGO.690)
- Mukherjee, S. et al., 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61 102059. (10.1016/j.eclinm.2023.102059)
2022
- Fennell, D. A. et al., 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48 101432. (10.1016/j.eclinm.2022.101432)
- Fennell, D. A. et al., 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52 101595. (10.1016/j.eclinm.2022.101595)
2021
- Adamson, D. et al., 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6 (4), pp.292-303. (10.1016/S2468-1253(21)00004-2)
- Mukherjee, S. et al., 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153 , pp.153-161. (10.1016/j.ejca.2021.05.020)
2018
- Lester, J. F. et al. 2018. Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC. [Meeting Abstract}. Journal of Clinical Oncology 36 (15_Sup) e20551. (10.1200/JCO.2018.36.15_suppl.e20551)
2017
- Svobodova, M. et al. 2017. Optimising trial recruitment with well-designed screening log: experiences from the ROCS study [Abstract]. Trials 18 (S1), pp.93-94. (10.1186/s13063-017-1902-y)
- Wills, L. et al., 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12 (1) 179. (10.1186/s13014-017-0916-7)
2016
- Fokas, E. et al., 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27 (sup. 2), pp.ii64.3-ii65. (10.1093/annonc/mdw199.214)
- Fokas, E. et al., 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120 (2), pp.212-216. (10.1016/j.radonc.2016.07.002)
- Gwynne, S. et al., 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89 20160020. (10.1259/bjr.20160020)
2015
- Fokas, E. et al., 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117 (3), pp.432-437. (10.1016/j.radonc.2015.08.026)
- Rees, J. et al., 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113 (4), pp.603-610. (10.1038/bjc.2015.258)
2014
- Adamson, D. et al., 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15 402. (10.1186/1745-6215-15-402)
2013
- Mukherjee, S. et al., 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31 (4) 230.
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87 (2), pp.S306. (10.1016/j.ijrobp.2013.06.804)
2012
- Gwynne, S. H. et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84 (4), pp.1037-1042. (10.1016/j.ijrobp.2012.01.094)
- Lester, J. F. et al., 2012. 156 The I-START trial: ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer [Abstract]. Lung Cancer 75 (S1), pp.S51. (10.1016/S0169-5002(12)70157-5)
2011
- Gwynne, S. et al., 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81 (2), pp.S67-S68. (10.1016/j.ijrobp.2011.06.135)
- Hurt, C. N. et al. 2011. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11 (1), pp.466. (10.1186/1471-2407-11-466)
2009
- Nixon, L. S. et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21 (3), pp.255-255. (10.1016/j.clon.2009.01.001,)
2004
- Bolton, C. E. et al. 2004. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170 (12), pp.1286-1293. (10.1164/rccm.200406-754OC)
2003
- Nixon, L. S. 2003. Neutrophil function in patients with cystic fibrosis and chronic pulmonary infection.. PhD Thesis , Cardiff University.
2002
- Ionescu, A. et al. 2002. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. American journal of respiratory and critical care medicine 165 (4), pp.495-500.
2000
- Ionescu, A. A. et al., 2000. Bone density, body composition, and inflammatory status in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine 162 (3), pp.789-794. (10.1164/ajrccm.162.3.9910118)
1999
- Abou-Hatab, K. et al., 1999. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment. European Journal of Clinical Pharmacology 54 , pp.937–941. (10.1007/s002280050578)
Articles
- Abou-Hatab, K. et al., 1999. Plasma esterases in cystic fibrosis: the impact of a respiratory exacerbation and its treatment. European Journal of Clinical Pharmacology 54 , pp.937–941. (10.1007/s002280050578)
- Adamson, D. et al., 2014. Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer (ROCS: Radiotherapy after Oesophageal Cancer Stenting): study protocol for a randomized controlled trial. Trials 15 402. (10.1186/1745-6215-15-402)
- Adamson, D. et al., 2021. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial. Lancet Gastroenterology and Hepatology 6 (4), pp.292-303. (10.1016/S2468-1253(21)00004-2)
- Bolton, C. E. et al. 2004. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 170 (12), pp.1286-1293. (10.1164/rccm.200406-754OC)
- Fennell, D. A. et al., 2022. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 48 101432. (10.1016/j.eclinm.2022.101432)
- Fennell, D. A. et al., 2022. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine 52 101595. (10.1016/j.eclinm.2022.101595)
- Fokas, E. et al., 2016. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?. Annals of Oncology 27 (sup. 2), pp.ii64.3-ii65. (10.1093/annonc/mdw199.214)
- Fokas, E. et al., 2015. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. Radiotherapy and Oncology 117 (3), pp.432-437. (10.1016/j.radonc.2015.08.026)
- Fokas, E. et al., 2016. Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology 120 (2), pp.212-216. (10.1016/j.radonc.2016.07.002)
- Gwynne, S. et al., 2011. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: A United Kingdom definitive chemoradiotherapy trial for esophageal cancer. International Journal of Radiation Oncology - Biology - Physics 81 (2), pp.S67-S68. (10.1016/j.ijrobp.2011.06.135)
- Gwynne, S. et al., 2016. Prospective review of radiotherapy trials through implementation of standardised multi-centre workflow and IT infrastructure. British Journal of Radiology 89 20160020. (10.1259/bjr.20160020)
- Gwynne, S. H. et al. 2012. Toward semi-automated assessment of target volume delineation in radiotherapy trials: the SCOPE 1 pretrial test case. International Journal of Radiation Oncology*Biology*Physics 84 (4), pp.1037-1042. (10.1016/j.ijrobp.2012.01.094)
- Holland-Hart, D. et al. 2024. The experiences of patients with oesophageal cancer receiving chemoradiotherapy treatment: a qualitative study embedded in the SCOPE2 trial. BMJ Open 14 (9) e076394. (10.1136/bmjopen-2023-076394)
- Hurt, C. N. et al. 2011. SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11 (1), pp.466. (10.1186/1471-2407-11-466)
- Ibrahim, H. et al., 2025. ColoCap: determining the diagnostic accuracy of colon capsule endoscopy compared with standard colonoscopy in patients at risk of colorectal disease – a study protocol. BMJ Open 15 (9) e104661. (10.1136/bmjopen-2025-104661)
- Ionescu, A. A. et al., 2000. Bone density, body composition, and inflammatory status in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine 162 (3), pp.789-794. (10.1164/ajrccm.162.3.9910118)
- Ionescu, A. et al. 2002. Pulmonary function, body composition, and protein catabolism in adults with cystic fibrosis. American journal of respiratory and critical care medicine 165 (4), pp.495-500.
- Lester, J. F. et al. 2018. Initial results of the phase ib/II, I-START trial: Isotoxic accelerated radiotherapy for the treatment of stage II-IIIb NSCLC. [Meeting Abstract}. Journal of Clinical Oncology 36 (15_Sup) e20551. (10.1200/JCO.2018.36.15_suppl.e20551)
- Lester, J. F. et al., 2012. 156 The I-START trial: ISoToxic Accelerated RadioTherapy in locally advanced non-small cell lung cancer [Abstract]. Lung Cancer 75 (S1), pp.S51. (10.1016/S0169-5002(12)70157-5)
- Mukherjee, S. et al., 2013. Comparison of investigator-delineated GTV in chemoradiotherapy (CRT) for locally advanced nonmetastatic pancreatic cancer (LANPC): Analysis of the pretrial test case for the SCALOP trial. Journal of Clinical Oncology 31 (4) 230.
- Mukherjee, S. et al., 2021. Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer 153 , pp.153-161. (10.1016/j.ejca.2021.05.020)
- Mukherjee, S. et al., 2023. Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial. EClinicalMedicine 61 102059. (10.1016/j.eclinm.2023.102059)
- Nixon, L. S. et al. 2013. The SCALOP Trial Plan Assessment Form (PAF) as a tool for Radiation Therapy Trials Quality Assurance (RTTQA). International Journal of Radiation Oncology*Biology*Physics 87 (2), pp.S306. (10.1016/j.ijrobp.2013.06.804)
- Nixon, L. S. et al. 2009. Implementation of a QA RT substudy for SCOPE 1; Preliminary results for test cases [Abstract]. Clinical Oncology 21 (3), pp.255-255. (10.1016/j.clon.2009.01.001,)
- O’Hara, J. T. et al., 2024. Transoral laser or robotic surgery outcomes for oropharyngeal carcinoma. JAMA Otolaryngology-Head and Neck Surgery 150 (11), pp.1002-1011. (10.1001/jamaoto.2024.3371)
- Rees, J. et al., 2015. Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer 113 (4), pp.603-610. (10.1038/bjc.2015.258)
- Svobodova, M. et al. 2017. Optimising trial recruitment with well-designed screening log: experiences from the ROCS study [Abstract]. Trials 18 (S1), pp.93-94. (10.1186/s13063-017-1902-y)
- Varley, M. et al. 2025. Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.. BMJ Open 15 (1) e084345. (10.1136/bmjopen-2024-084345)
- Wallis, L. et al., 2026. The QuinteT recruitment intervention and its role in oncology randomised controlled trials [Editorial]. Clinical Oncology 49 103976. (10.1016/j.clon.2025.103976)
- Wills, L. et al., 2017. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy. Radiation Oncology 12 (1) 179. (10.1186/s13014-017-0916-7)
Conferences
- Ajakaiye, A. et al., 2024. Pressurised intraperitoneal aerosolised chemotherapy in the management of cancer of the colon, ovary and stomach: phase II randomised controlled trial of efficacy in peritoneal metastases. Presented at: International Society of Gynecologic Cancer 2024 Annual Global Meeting Dublin, Ireland 16-18 October 2024. Vol. 34.BMJ Publishing Group. , pp.A350-A351. (10.1136/ijgc-2024-IGCS.611)
- Jones, S. E. F. et al. 2023. Launching the PICCOS trial: PIPAC in cancers of the colon, ovary and stomach. Presented at: European Society of Gynaecological Society Congress Istanbul, Turkey 28 September - 01 October 2023. BMJ Publishing Group(10.1136/ijgc-2023-ESGO.690)
Thesis
- Nixon, L. S. 2003. Neutrophil function in patients with cystic fibrosis and chronic pulmonary infection.. PhD Thesis , Cardiff University.
Biography
Education and Qualifications
2006: PGCE/Cert Ed (PCET) (University of Wales Institute Cardiff)
2004: PhD Neutrophil function in patients with cystic fibrosis and chronic pulmonary infection. (Cardiff University)
1992: BSc (Hons) (Pharmacology) (University of East London)
1989: HNC (Applied Biology) (University of Hertfordshire)
Career Overview
Senior Trial Manager (July 2010 to date), Wales Cancer Trials Unit, Centre for Trials Research
Trial Manager (Sept 2006 to June 2010), Wales Cancer Trials Unit.
Research Associate (Nov 1992 to Sept 2006), Department of Respiratory Medicine, Cardiff University.
Lecturer (occasional, part time) Biomedical Science (Sept 2005 to Mar 08), University of Wales Institute Cardiff
Associate Lecturer, Open University. SK121:Understanding Cardiovascular disease (September 2007 to October 2010); SDK125: Introduction to Healthcare studies (September 2008 to June 2015)
Assistant Pharmacologist, Glaxo Group Research (now GSK), (November 1987 to Octover 1992)
Professional memberships
British Society of Immunology, member 14311, 1997